Thymosin Alpha-1

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Thymosin Alpha-1 — Thymic Immunomodulatory Peptide and TLR Pathway Activator

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5 of bovine thymic tissue by Allan Goldstein and colleagues at George Washington University in 1972 — the same laboratory that later characterized the actin-regulatory fraction that would eventually yield thymosin beta-4. Tα1 is N-terminally acetylated in its biologically active form and is the dominant immunostimulatory constituent of the thymic thymosin fraction. The compound has been approved for clinical use in more than 35 countries under the brand name Zadaxin (thymalfasin) as an adjunct in hepatitis B, hepatitis C, and cancer immunotherapy — a regulatory approval base that provides unusually detailed human pharmacology data for a research peptide. In the United States it remains unapproved. Tα1 is mechanistically distinct from thymosin beta-4: where beta-4 acts on actin polymerization and tissue repair pathways, alpha-1 operates primarily at the innate-adaptive immune interface, shifting the balance toward Th1-dominant immune phenotypes through dendritic cell and T cell modulation.

Why Thymosin Alpha-1’s TLR-Mediated Mechanism Matters

Tα1 engages Toll-like receptors 7 and 9 (TLR7/TLR9) on plasmacytoid and myeloid dendritic cells, triggering MyD88-dependent NF-κB activation and downstream cytokine production. This places Tα1 mechanistically upstream of T cell differentiation: by programming dendritic cell output toward IL-12 and IFN-α, it shifts the Th1/Th2 balance without directly acting on T cells themselves. The downstream consequence is expansion of cytotoxic T lymphocyte (CTL) and NK cell populations and suppression of Th2-associated IL-4/IL-10 cytokine profiles. This makes it a tractable tool compound for research models examining innate-to-adaptive immune transitions, Treg dynamics, and antiviral immune response architecture.

Research Applications

Thymosin Alpha-1 is used in studies examining:

• Innate-to-adaptive immune transition mechanisms via TLR7/TLR9 signaling
• Th1/Th2 balance modulation in infection and autoimmunity models
• Vaccine adjuvant activity and antigen-presenting cell priming
• Antiviral immune response in hepatitis B and hepatitis C model systems
• Cancer immunotherapy — CTL and NK cell enhancement in tumor challenge models
• Immunosenescence and immune reconstitution in aging or immunosuppressed research subjects
• Sepsis immunoparalysis models — Tα1 studied for reversing Th1 anergy in late-phase sepsis

Specifications

Reconstitution

Thymosin Alpha-1 arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 2mg vial + 1mL BAC water = 2mg/mL solution; 5mg vial + 2.5mL BAC water = 2mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

The standard research framework for Tα1 derives from the Zadaxin (thymalfasin) clinical literature, including hepatitis B and hepatitis C trials and sepsis immunoparalysis studies. The twice-weekly subcutaneous protocol is the most consistently replicated across published clinical research.

• Dose range (clinical literature): 1.6mg SC twice weekly (standard Zadaxin protocol in hepatitis and immunocompromise research)
• Frequency: Twice weekly in published hepatitis and cancer immunotherapy literature; daily dosing seen in sepsis models
• Study duration: 6-month courses in hepatitis research; shorter 4–8 week windows in cancer and sepsis models

Research Stacks

Thymosin Alpha-1 is commonly paired in research settings with:

• Epithalon — Epithalon activates telomerase and modulates pineal peptide signaling; pairing with Thymosin Alpha-1’s thymic T-cell maturation and innate immune priming activity is used in longevity-focused research models examining immune competence alongside genomic stability mechanisms.
• KPV — KPV is an alpha-MSH-derived tripeptide with direct anti-inflammatory and gut-barrier protective properties; combined with Thymosin Alpha-1’s immunomodulatory and dendritic cell activation profile, the pairing is studied in models of mucosal immune regulation and inflammatory resolution.
• LL-37 — LL-37 is a cathelicidin-derived antimicrobial peptide with broad innate immune signaling activity; pairing with Thymosin Alpha-1 provides researchers a model to study complementary innate and adaptive immune pathway engagement in infection and immune-surveillance research.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.